logo
Sign in

NATCO PHARMA LTD. (NATCOPHARM) financials

NATCO PHARMA LTD. (NATCOPHARM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.[1]NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[…

  • Market Cap: ₹15,400Cr.
  • Current Price: ₹785
  • Stock P/E: 17.3
  • ROE: 16.4%
  • ROCE: 16.8%
  • Book Value: ₹436
  • Dividend Yield: 0.64%
  • 52W High / Low: ₹1,217/779

In Jun 2026, NATCO PHARMA LTD. (NATCOPHARM) reported sales ₹597 Cr and net profit ₹75 Cr.

Annual TTM: sales ₹2,998 Cr, net profit ₹892 Cr.

Shareholding: Promoters 49.39% (Sep 2026), FIIs 15.99% (Sep 2026), DIIs 6.16% (Sep 2026), Public 28.46% (Sep 2026), No. of Shareholders 4,04,135% (Sep 2026).

NATCOPHARM quarterly results (₹ Cr.)
CategorySep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,2934081,1571,1931,264529609597
Expenses502378596653712408516491
Operating Profit7912956154055212092106
OPM %61%7%48%45%44%23%15%18%
Other Income51168626093557348
Interest33931281010
Depreciation4244945448424643
Profit before tax797150521543586125110102
Tax %17%17%18%15%15%15%-91%27%
Net Profit66112542846450110721075
EPS in Rs33.706.3721.8223.6525.535.4510.683.80
Raw PDF————————
NATCOPHARM profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,7901,6541,7682,3513,5694,0943,5952,998
Expenses1,2121,2361,5551,5061,9291,9502,2652,127
Operating Profit5784182138451,6402,1441,330871
OPM %32%25%12%36%46%52%37%29%
Other Income1241019586102321256270
Interest211113914203239
Depreciation98115138151172220190178
Profit before tax5833921567711,5552,2261,364923
Tax %19%21%11%17%16%17%6%—
Net Profit4743101396371,3071,8501,282892
EPS in Rs23.8015.506.9631.8766.6094.3165.3245.46
Dividend Payout %26%31%59%16%13%6%7%—
NATCOPHARM balance sheet (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital3636363636363636
Reserves3,5273,8334,0554,1554,6665,5567,2988,517
Borrowings384314256400161366275709
Other Liabilities4084634053875255966611,026
Total Liabilities4,3564,6474,7524,9785,3886,5548,27010,287
Fixed Assets1,2151,5742,0062,1742,2342,2872,5172,615
CWIP63851822312963134225293
Investments2441913375506587428553,265
Other Assets2,2592,3632,1862,1252,4343,3924,6734,114
Total Assets4,3564,6474,7524,9785,3886,5548,27010,287
NATCOPHARM cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity699422184587841,1961,6621,776
Cash from Investing Activity-645-165-3-92-437-960-1,444-2,078
Cash from Financing Activity-52-261-18336-347-237-212302
Net Cash Flow1-4-311-160
Free Cash Flow26589-14-1246688621,2491,392
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit107%91%62%42%110%88%94%160%
NATCOPHARM shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters49.62%49.56%49.56%49.48%49.48%49.41%49.41%49.39%
FIIs17.94%17.49%15.52%14.09%15.16%17.37%16.99%15.99%
DIIs5.59%5.64%5.81%5.87%5.39%5.46%5.63%6.16%
Public26.88%27.30%29.12%30.56%29.97%27.74%27.97%28.46%
No. of Shareholders3,45,3324,05,2224,29,4344,19,6994,24,1674,10,9704,03,1664,04,135
NATCOPHARM key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days901098811912311010577
Inventory Days547482562476424379395460
Days Payable21721510296126116138232
Cash Conversion Cycle420376548499422373362305
Working Capital Days215310297268213153149101
ROCE %24%14%9%3%16%29%32%17%
NATCOPHARMUpdated 19 Oct 2026, 5:50

Natco Pharma Ltd.

Market Cap

₹15,400Cr.

Current Price

₹785

High / Low

₹1,217/779

Stock P/E

17.3

ROE16.4%
ROCE16.8%
Book Value₹436
Face Value₹2.00
Dividend Yield0.64%

About

NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.[1]NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business.[2]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days968887106901098811912311010577
Inventory Days424501215400547482562476424379395460
Days Payable24738516023121721510296126116138232
Cash Conversion Cycle274205142275420376548499422373362305
Working Capital Days208673222215310297268213153149101
ROCE %18%18%39%34%24%14%9%3%16%29%32%17%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of NATCO PHARMA LTD. (NATCOPHARM)?

The reported market capitalisation for NATCO PHARMA LTD. (NATCOPHARM) is ₹15,400Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of NATCOPHARM?

The current price shown for NATCO PHARMA LTD. (NATCOPHARM) on Fincrux is ₹785 with a 52-week high/low of ₹1,217/779.

What is the P/E ratio of NATCO PHARMA LTD. (NATCOPHARM)?

The stock P/E for NATCO PHARMA LTD. (NATCOPHARM) is 17.3 on Fincrux, with ROE at 16.4% and ROCE at 16.8%.

What were NATCOPHARM latest quarterly results?

For Jun 2026, NATCO PHARMA LTD. (NATCOPHARM) reported sales ₹597 Cr and net profit ₹75 Cr (figures in ₹ crore unless noted).

What are NATCOPHARM annual sales and net profit?

For TTM, NATCO PHARMA LTD. (NATCOPHARM) shows sales of ₹2,998 Cr and net profit of ₹892 Cr on the Fincrux profit & loss statement.

Who owns NATCO PHARMA LTD. (NATCOPHARM)?

Latest shareholding for NATCO PHARMA LTD. (NATCOPHARM) on Fincrux: Promoters 49.39% (Sep 2026), FIIs 15.99% (Sep 2026), DIIs 6.16% (Sep 2026), Public 28.46% (Sep 2026), No. of Shareholders 4,04,135% (Sep 2026).

Where can I find NATCO PHARMA LTD. (NATCOPHARM) financials?

NATCO PHARMA LTD. (NATCOPHARM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show NATCOPHARM balance sheet and cash flow?

Yes. The NATCO PHARMA LTD. (NATCOPHARM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 19 October 2026 at 5:50

Designed & Shipped by Harshit Bansal